Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
V. Moreno
Observed names:
Moreno, V.,
Vanessa P Moreno,
Vanessa P. Moreno
Institution:
Hospital Universitario Fundación Jiménez Díaz
Observed institutions:
Hospital Universitario Fundación Jiménez Díaz,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Universidad Autónoma de Madrid
ORCID:
0000-0003-4496-0794
Observed ORCID:
0000-0003-4496-0794
OpenAlex ID:
A5063627366
Factores de riesgo vascular en pacientes con ictus isquémico. Distribución según edad, sexo y subtipo de ictus
2008
·
Vanessa P. Moreno
, Aránzazu García Raso
, et al.
·
Revista de Neurología
·
33
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
2022
·
M. Simonelli
, E. Garralda
, et al.
·
ESMO Open
·
31
PDF
Dostarlimab for the treatment of endometrium cancer and other solid tumors
2021
·
Rubio-Perez, J.
, Hernandez, R.
, et al.
·
Drugs of today
·
17
IL-6 as a Biomarker of Ischemic Cerebrovascular Disease
2008
·
Vanessa P Moreno
, Dolores Subirá
, et al.
·
Biomarkers in Medicine
·
16
Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
2018
·
T.K. Owonikoko
, K.P. Papadopoulos
, et al.
·
Annals of Oncology
·
11
Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors
2022
·
E. Garralda
, V. Moreno
, et al.
·
European Journal of Cancer
·
10
PDF
Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study
2018
·
A.R. He
, G.J. Weiss
, et al.
·
Annals of Oncology
·
9
Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
2018
·
V. Moreno
, M. Gil-Martin
, et al.
·
Annals of Oncology
·
5
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
2022
·
A. Schram
, M. Borad
, et al.
·
European Journal of Cancer
·
4
1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
2020
·
C. Le Tourneau
, D. Rischin
, et al.
·
Annals of Oncology
·
4
PDF
MA11.09 Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer
2021
·
D. Tan
, A. Farago
, et al.
·
Journal of Thoracic Oncology
·
2
PDF
11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study
2020
·
E. Angevin
, S. Groenland
, et al.
·
Annals of Oncology
·
2
PDF
MA06.12 Updated Efficacy, Safety, and Biomarker Analysis in Patients with TRK Fusion Lung Cancer Treated with Larotrectinib
2024
·
J.J. Lin
, D.S.W. Tan
, et al.
·
Journal of Thoracic Oncology
·
1
528O CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
2020
·
A. Hollebecque
, J.S. de Bono
, et al.
·
Annals of Oncology
·
1
MA02.04 Updated Efficacy, Safety, and Genomic Data in Patients With Trk Fusion Lung Cancer Treated With Larotrectinib
2025
·
J.J. Lin
, V. Moreno
, et al.
·
Journal of Thoracic Oncology
61P Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib
2022
·
V. Moreno
, J.J. Lin
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
16
Citation count:
146
H-index:
7
I10-index:
6
Year
Topic
Type